This new update furthers Genomenon’s ability to catalogue a complete dataset of all “Genomic Associations” supported by medical evidence. These associations help clinical labs more accurately and rapidly diagnose patients, and pharmaceutical companies make ground-breaking discoveries in the effective treatment of cancer and genetic diseases. Mastermind was launched in 2017 with the ability to uncover associations between diseases, genes, and variants, and has since added ACMG/AMP classification, phenotypes, therapies, and now CNV associations. Each new component of association data increases the power of Mastermind to enable users to find genetic evidence, test or generate hypotheses, and draw clinical conclusions with confidence.

Copy-number variations are a vital component to any clinical interpretation pipeline. They are highly heterogeneous, and current genetic databases are difficult to navigate and contain limited or outdated information. This makes interpretation of CNVs extremely challenging and time-consuming. In addition, the evolving and inconsistent nomenclature for CNV reporting over time has created significant challenges in searching for evidence in the literature, which can result in missing information relevant to diagnosis and interpretation.

This new feature in the Mastermind Genomic Search Engine allows users to identify CNV citations from full-text articles no matter how authors have described them, and to discover how they are associated with clinical diseases and phenotypes.

Genomenon will present a Mastermind Masterclass on the new CNV search capability on Thursday, October 15, 2020. Learn more and register.

About Genomenon

Genomenon is a genomic health IT company that keeps pace with the constant advancements made in genomics and connects that research to patient DNA to help diagnose and treat patients with rare genetic diseases and cancer.

The Mastermind Genomic Search Engine^® is used by hundreds of genetic labs worldwide to accelerate diagnosis, increase diagnostic yield, and assure repeatability in reporting genetic testing results.

Mastermind Genomic Landscapes^TM inform pharmaceutical and bio-pharma companies on precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence.

Genomenon was named 2020 Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.